Stenbøg E V, Windelborg B, Hørlyck A, Herlin T
Department of Paediatrics, Aarhus University Hospital, Section SKS, DK-8200 Aarhis N, Denmark.
Scand J Rheumatol. 2006 Jul-Aug;35(4):318-21. doi: 10.1080/03009740600588228.
In Kawasaki disease (KD), a systemic vasculitis of childhood, serum levels of proinflammatory cytokines such as tumour necrosis factor alpha (TNFalpha) are elevated during the acute phase of the disease. Although the majority of children recover completely from a single dose of intravenous immunoglobulin (IVIG), the treatment is not always effective. In refractory cases of KD there are no documented treatment guidelines. A future role of biological agents directed against proinflammatory cytokines has recently been suggested by the American Heart Association (AHA). We describe two infants with severe KD, complicated by coronary as well as extracoronary aneurysms, who responded neither to repeated treatment with IVIG plus aspirin nor to corticosteroids. The children were subsequently treated with infliximab. In both cases, the effect was prompt and long-lasting. Clinical improvement was seen within a few days after the first dose, and regression of the aneurysms occurred within weeks.
在川崎病(KD),一种儿童期的全身性血管炎中,促炎细胞因子如肿瘤坏死因子α(TNFα)的血清水平在疾病急性期会升高。尽管大多数儿童单次静脉注射免疫球蛋白(IVIG)后可完全康复,但该治疗并非总是有效。在KD的难治性病例中,尚无记录在案的治疗指南。美国心脏协会(AHA)最近提出了针对促炎细胞因子的生物制剂的未来作用。我们描述了两名患有严重KD且并发冠状动脉和冠状动脉外动脉瘤的婴儿,他们对IVIG加阿司匹林的重复治疗以及皮质类固醇均无反应。这两名儿童随后接受了英夫利昔单抗治疗。在这两个病例中,效果迅速且持久。首次给药后几天内可见临床改善,数周内动脉瘤消退。